New mpox vaccine trial aims to protect High-Risk groups in colombia
NCT ID NCT06223919
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 19 times
Summary
This study tests whether the LC16m8 vaccine can prevent mpox (monkeypox) in about 8,700 adults at high risk, including those with HIV. Participants are randomly assigned to get the vaccine right away or after a delay. Researchers will compare infection rates and side effects between the two groups over 180 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinica Universitaria Colombia - Centro Medico Teusaquillo
Bogotá, Bogota D.C., Colombia
-
Hospital Universitario San Ignacio
Bogotá, Bogota D.C., Colombia
-
Infecto Clinicos
Bogotá, Bogota D.C., Colombia
Conditions
Explore the condition pages connected to this study.